[144] Twist Bioscience Corporation SEC Filing

Rhea-AI Filing Summary

Twist Bioscience (TWST) filed a Form 144 reporting a proposed sale of 853 shares of common stock through Fidelity Brokerage Services on NASDAQ, with an aggregate market value of $23,620.68 and an approximate sale date of 08/25/2025. The filing shows these 853 shares were acquired on 08/22/2025 upon restricted stock vesting as part of compensation and were paid for on 08/22/2025. The filer previously sold small blocks of common stock on 06/06/2025, 08/04/2025, and 08/21/2025 for gross proceeds of $7,143.66, $5,275.72, and $6,179.48 respectively. The notice includes the required representation that the seller is not aware of any undisclosed material adverse information.

Positive

• Securities were acquired through restricted stock vesting, indicating the shares stem from compensation rather than an external purchase
• Filer provided historical recent sale details, improving transparency about prior dispositions (06/06/2025, 08/04/2025, 08/21/2025)

Negative

• Insider proposes to sell shares (853 shares, $23,620.68 aggregate market value), which may be interpreted by some investors as monetization of holdings

Insights

Securities Analyst

TL;DR: Routine insider notice for sale of vested restricted shares; transaction size is small relative to a public float.

The Form 144 documents a proposed sale of 853 shares resulting from restricted stock vesting and lists recent small dispositions by the same person. This is a standard Rule 144 filing for compliance with resale rules. The filing does not disclose any material, nonpublic information and provides broker, timing, and historical-sale details necessary for investor transparency. Impact on capitalization and trading liquidity appears immaterial based on the reported size and frequency of prior small sales.

Corporate Governance Expert

TL;DR: Compliance-focused disclosure showing an insider monetizing vested compensation under Rule 144.

The notice indicates the securities were acquired as compensation via restricted stock vesting and are now being registered for sale under Rule 144 through a broker. The filing includes the standard seller representation about lack of undisclosed material adverse information and lists prior small sales, which helps demonstrate routine liquidity events rather than abrupt insider-driven changes. From a governance perspective, this is a routine transparency filing rather than a governance red flag.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Fidelity Brokerage Services LLC 900 Salem Street Smithfield RI 02917	853	23620.68	60360925	08/25/2025	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	08/22/2025	Restricted Stock Vesting	Issuer			853	08/22/2025	Compensation

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Robert F. Werner 681 Gateway Blvd South San Francisco CA 94080	Common	06/06/2025	225	7143.66
Robert F. Werner 681 Gateway Blvd South San Francisco CA 94080	Common	08/04/2025	186	5275.72
Robert F. Werner 681 Gateway Blvd South San Francisco CA 94080	Common	08/21/2025	238	6179.48

144: Remarks and Signature

Remarks

Date of Notice

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does Twist Bioscience's (TWST) Form 144 report?

The filing reports a proposed sale of 853 common shares with an aggregate market value of $23,620.68 through Fidelity on 08/25/2025.

How were the 853 shares acquired according to the filing?

The shares were acquired on 08/22/2025 via restricted stock vesting and the payment nature is listed as compensation.

Has the filer sold shares of TWST recently?

Yes. The filing lists sales by Robert F. Werner of 225 shares on 06/06/2025 for $7,143.66, 186 shares on 08/04/2025 for $5,275.72, and 238 shares on 08/21/2025 for $6,179.48.

Through which broker will the proposed sale occur?

The proposed sale is to be executed via Fidelity Brokerage Services LLC (900 Salem Street, Smithfield RI).

Does the filing state whether any material nonpublic information exists?

By signing the notice, the person represents they do not know of any material adverse information about the issuer that has not been publicly disclosed.